DNA vaccine reduces both toxic proteins linked to Alzheimer's
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer's disease, according to research that scientists say may pave the way to a clinical trial. A new study by UT Southwestern's Peter O'Donnell Jr. Brain Institute shows that a vaccine delivered to the skin prompts an immune response that reduces buildup of harmful tau and beta-amyloid—without triggering severe brain swelling that earlier antibody treatments caused in some patients. "This study is the culmination of a decade of research that has repeatedly demonstrated that this vaccine can effectively and safely target in animal models what we think may cause Alzheimer's disease," said Dr. Roger Rosenberg, founding Director of the Alzheimer's Disease Center at UT Southwestern. "I believe we're getting close to testing this therapy in people."
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer's disease, according to research that scientists say may pave the way to a clinical trial. A new study by UT Southwestern's Peter O'Donnell Jr. Brain Institute shows that a vaccine delivered to the skin prompts an immune response that reduces buildup of harmful tau and beta-amyloid—without triggering severe brain swelling that earlier antibody treatments caused in some patients. "This study is the culmination of a decade of research that has repeatedly demonstrated that this vaccine can effectively and safely target in animal models what we think may cause Alzheimer's disease," said Dr. Roger Rosenberg, founding Director of the Alzheimer's Disease Center at UT Southwestern. "I believe we're getting close to testing this therapy in people."
No comments:
Post a Comment